Passive antibody therapy in COVID-19 #MMPMID32533109
Abraham J
Nat Rev Immunol 2020[Jul]; 20 (7): 401-403 PMID32533109show ga
For over a century, transfusion of convalescent plasma from recovered individuals has been tried as a therapeutic approach when a novel pathogen emerges. As the world awaits SARS-CoV-2 vaccines to be tested and safely deployed, the rapidity with which antiviral monoclonal antibodies can be isolated and engineered offers an attractive alternative option for passive immunization.